Scribe Therapeutics, Inc. (SCTX)

Data as of Jul 29, 2026, from SEC Form 4 filings.

NasdaqBiological Products, (No Diagnostic Substances)No open-market insider trades (90d)Watch SCTX

See up to 3 months of SCTX. The 7-day demo opens the 1M and 3M ranges and puts SCTX on your watchlist.

Latest SCTX insider trades

AH Bio Fund II, L.P. - 10% Owner
Open-market purchase$5.00M
Jul 27, 2026
Carl L. Gordon - Director

About Scribe Therapeutics, Inc. (SCTX)

Scribe Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of in vivo CRISPR-based genetic medicines. Its research and development activities focus on cardiovascular and metabolic diseases, including atherosclerotic cardiovascular disease (ASCVD). The company's product pipeline includes STX-1150, a CRISPR-based product candidate that utilizes its ELXR epigenetic silencing technology.

Headquarters: ALAMEDA, CA
Listed: 2026
Exchange: Nasdaq
Sector: Health Care

https://www.scribetx.com SEC filings for SCTX on EDGAR

SCTX Form 4 activity by transaction type, last 90 days

No Form 4 activity for SCTX in the last 90 days.

SCTX insider transactions (Form 4)

13 Form 4 filings on record, the earliest from Jul 28, 2026, newest first.

Traded	Insider	Transaction	Security	Shares	Price	Value
Jul 27, 2026	AH Bio Fund II, L.P. - 10% Owner	Other	Common Stock	2,051,742	-^{footnote F1}	-
Jul 27, 2026	AH Bio Fund II, L.P. - 10% Owner	Other	Common Stock	697,650	-^{footnote F1}	-
Jul 27, 2026	AH Bio Fund II, L.P. - 10% Owner	Open-market purchase	Common Stock	333,333	$15.00	$5.00M
Jul 27, 2026	AH Bio Fund II, L.P. - 10% Owner	Other	Series A Preferred Stock	12,150,003	$0.00	-
Jul 27, 2026	AH Bio Fund II, L.P. - 10% Owner	Other	Series B Preferred Stock	4,131,344	$0.00	-
Footnote F1 (price): Series A Preferred Stock and Series B Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a 5.9218-for-one basis, and had no expiration date.
Jul 27, 2026	Carl L. Gordon - Director	Other	Common Stock	348,825	-^{footnote F1}	-
Jul 27, 2026	Carl L. Gordon - Director	Open-market purchase	Common Stock	1,000,000^{footnote F2}	$15.00	$15.00M
Jul 27, 2026	Carl L. Gordon - Director	Other	Series B Preferred Stock	2,065,672	$0.00	-
Footnote F1 (price): Each share of Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a one-for-0.1689 basis upon the closing of the Issuer's initial public offering on July 27, 2026 without payment of consideration. The Series B Preferred Stock has no… Full note on SEC EDGAR Footnote F2 (shares): Reflects shares of the Issuer's Common Stock purchased in the Issuer's initial public offering.
Jul 27, 2026	ORBIMED ADVISORS LLC - Director	Other	Common Stock	348,825	-^{footnote F1}	-
Jul 27, 2026	ORBIMED ADVISORS LLC - Director	Open-market purchase	Common Stock	1,000,000^{footnote F2}	$15.00	$15.00M
Jul 27, 2026	ORBIMED ADVISORS LLC - Director	Other	Series B Preferred Stock	2,065,672	$0.00	-
Footnote F1 (price): Each share of Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a one-for-0.1689 basis upon the closing of the Issuer's initial public offering on July 27, 2026 without payment of consideration. The Series B Preferred Stock has no… Full note on SEC EDGAR Footnote F2 (shares): Reflects shares of the Issuer's Common Stock purchased in the Issuer's initial public offering.
Jul 27, 2026	Jennifer A. Doudna - 10% Owner	Other	Common Stock	12,511	-^{footnote F1}	-
Jul 27, 2026	Jennifer A. Doudna - 10% Owner	Other	Series A-1 Preferred Stock	74,088	-^{footnote F1}	-
Footnote F1 (price): Each share of Series A-1 Preferred Stock is convertible into Common Stock on a one-for 0.1689 basis at the option of the holder, and will convert automatically upon closing of the Issuer's initial public offering without payment of consideration. The Series A-1 Preferred Stock… Full note on SEC EDGAR
Jul 24, 2026	Behzad Aghazadeh - Director	Open-market purchase	Common Stock, par value $0.0001 per share	2,333,333	$15.00^{footnote F1}	$35.00M
Jul 24, 2026	Behzad Aghazadeh - Director	Open-market purchase	Common Stock, par value $0.0001 per share	50,000	$22.31^{footnote F2}	$1.12M
Jul 28, 2026	Behzad Aghazadeh - Director	Open-market purchase	Common Stock, par value $0.0001 per share	7,905	$18.25^{footnote F2}	$144K
Footnote F1 (price): The shares reported on this line were purchased from underwriters in the Issuer's initial public offering (the "IPO") at the initial public offering price of $15.00 per share. Of such shares, 2,066,666 shares were purchased on behalf of Avoro Life Sciences Fund LLC ("Avoro Life… Full note on SEC EDGAR Footnote F2 (price): The shares reported on these lines were purchased on behalf of Avoro Life Sciences in open market transactions on the dates provided in Column 2.
Mar 13, 2026	Brett Staahl - 10% Owner	Grant or award	Stock Option (Right to Buy)	4,755	$0.00	-
Jul 23, 2026	Brett Staahl - 10% Owner	Grant or award	Stock Option (Right to Buy)	19,385	$0.00	-
Jul 23, 2026	Brett Staahl - 10% Owner	Grant or award	Performance-based Stock Option (Right to Buy)	19,385	$0.00	-
Jul 23, 2026	Svetlana Lucas - Officer	Open-market purchase	Common Stock	3,000	$15.00	$45K
Mar 13, 2026	Svetlana Lucas - Officer	Grant or award	Stock Option (Right to Buy)	9,547	$0.00	-
Jul 23, 2026	Svetlana Lucas - Officer	Grant or award	Stock Option (Right to Buy)	109,426	$0.00	-
Jul 23, 2026	Svetlana Lucas - Officer	Grant or award	Performance-based Stock Option (Right to Buy)	109,426	$0.00	-
Mar 13, 2026	Benjamin L. Oakes - Officer	Grant or award	Stock Option (Right to Buy)	12,969	$0.00	-
Jul 23, 2026	Benjamin L. Oakes - Officer	Grant or award	Stock Option (Right to Buy)	264,784	$0.00	-
Jul 23, 2026	Benjamin L. Oakes - Officer	Grant or award	Performance-based Stock Option (Right to Buy)	429,599	$0.00	-
Jul 23, 2026	Carl L. Gordon - Director	Grant or award	Stock Option (Right to Buy)	14,725	$0.00	-
Jul 23, 2026	James Dean Watson - Director	Grant or award	Stock Option (Right to Buy)	14,725	$0.00	-
Jul 23, 2026	Joshua Bleharski - Director	Grant or award	Stock Option (Right to Buy)	14,725	$0.00	-
Jul 23, 2026	David Parrot - Officer	Open-market purchase	Common Stock	1,333	$15.00	$20K
Jul 23, 2026	David Parrot - Officer	Open-market purchase	Common Stock	1,333	$15.00	$20K
Mar 13, 2026	David Parrot - Officer	Grant or award	Stock Option (Right to Buy)	8,909	$0.00	-
Jul 23, 2026	David Parrot - Officer	Grant or award	Stock Option (Right to Buy)	109,426	$0.00	-
Jul 23, 2026	David Parrot - Officer	Grant or award	Performance-based Stock Option (Right to Buy)	109,426	$0.00	-
Jul 23, 2026	Behzad Aghazadeh - Director	Grant or award	Stock Option (Right to Buy)	14,725	$0.00	-

Recent SCTX Form 8-K filings

Read SCTX company news

Sep 2, 2026Item 2.02, 9.01

Read the filing on SEC EDGAR

Jul 27, 2026Item 5.03, 9.01

Read the filing on SEC EDGAR

SCTX insider trading FAQ

What is the latest insider trade for SCTX?

Scribe Therapeutics, Inc. (SCTX) has filed no insider reports in the last 90 days. The most recent on record is dated 29 July 2026. The full record for SCTX runs to 13 Form 4 filings, the earliest from 28 July 2026. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.

How many insiders are buying SCTX stock?

No insider purchases of SCTX were filed in the last 90 days. 9 purchases are on record for this company.

How many insiders are selling SCTX stock?

No insider sales of SCTX were filed in the last 90 days.

Where can I see SCTX SEC filings (Form 4, 10-K, 10-Q, 8-K)?

This page collects SCTX Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.

More Health Care companies with insider activity

Recent insider filings

The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.

Jul 29, 2026 - AH Bio Fund II, L.P. view on EDGAR
Jul 29, 2026 - Carl L. Gordon view on EDGAR
Jul 29, 2026 - ORBIMED ADVISORS LLC view on EDGAR
Jul 29, 2026 - Jennifer A. Doudna view on EDGAR
Jul 29, 2026 - Behzad Aghazadeh view on EDGAR
Jul 28, 2026 - Brett Staahl view on EDGAR
Jul 28, 2026 - Svetlana Lucas view on EDGAR
Jul 28, 2026 - Benjamin L. Oakes view on EDGAR
Jul 28, 2026 - Carl L. Gordon view on EDGAR

Related companies with recent insider activity

Learn more

What the Form 4 transaction codes mean: Grants, option exercises, gifts and tax withholding are not trades on the market. The codes say which is which.
Insider activity in Health Care: Where SCTX's peers are being bought and sold.
Every recent Form 4: The market-wide feed, updated as filings arrive from SEC EDGAR.

Follow SCTX with a 7-day demo

SCTX on your watchlist
Every SCTX Form 4 filing on record
Up to 3 months of SCTX price history
The daily trading plan of ranked insider buys, on a delay, with the plan archive

Start 7-day demoCard required. Your card is never charged for the demo.

Traded

Insider

Transaction

Security

Price

Value

Jul 27, 2026

AH Bio Fund II, L.P. - 10% Owner

Other

Common Stock

2,051,742

-^{footnote F1}

Jul 27, 2026

AH Bio Fund II, L.P. - 10% Owner

Other

Common Stock

697,650

-^{footnote F1}

Jul 27, 2026

AH Bio Fund II, L.P. - 10% Owner

Open-market purchase

Common Stock

333,333

$15.00

$5.00M

Jul 27, 2026

AH Bio Fund II, L.P. - 10% Owner

Other

Series A Preferred Stock

12,150,003

$0.00

Jul 27, 2026

AH Bio Fund II, L.P. - 10% Owner

Other

Series B Preferred Stock

4,131,344

$0.00

Footnote F1 (price): Series A Preferred Stock and Series B Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a 5.9218-for-one basis, and had no expiration date.

Jul 27, 2026

Carl L. Gordon - Director

Other

Common Stock

348,825

-^{footnote F1}

Jul 27, 2026

Carl L. Gordon - Director

Open-market purchase

Common Stock

1,000,000^{footnote F2}

$15.00

$15.00M

Jul 27, 2026

Carl L. Gordon - Director

Other

Series B Preferred Stock

2,065,672

$0.00

Footnote F1 (price): Each share of Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a one-for-0.1689 basis upon the closing of the Issuer's initial public offering on July 27, 2026 without payment of consideration. The Series B Preferred Stock has no… Full note on SEC EDGAR
Footnote F2 (shares): Reflects shares of the Issuer's Common Stock purchased in the Issuer's initial public offering.

Jul 27, 2026

ORBIMED ADVISORS LLC - Director

Other

Common Stock

348,825

-^{footnote F1}

Jul 27, 2026

ORBIMED ADVISORS LLC - Director

Open-market purchase

Common Stock

1,000,000^{footnote F2}

$15.00

$15.00M

Jul 27, 2026

ORBIMED ADVISORS LLC - Director

Other

Series B Preferred Stock

2,065,672

$0.00

Footnote F1 (price): Each share of Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a one-for-0.1689 basis upon the closing of the Issuer's initial public offering on July 27, 2026 without payment of consideration. The Series B Preferred Stock has no… Full note on SEC EDGAR
Footnote F2 (shares): Reflects shares of the Issuer's Common Stock purchased in the Issuer's initial public offering.

Jul 27, 2026

Jennifer A. Doudna - 10% Owner

Other

Common Stock

12,511

-^{footnote F1}

Jul 27, 2026

Jennifer A. Doudna - 10% Owner

Other

Series A-1 Preferred Stock

74,088

-^{footnote F1}

Footnote F1 (price): Each share of Series A-1 Preferred Stock is convertible into Common Stock on a one-for 0.1689 basis at the option of the holder, and will convert automatically upon closing of the Issuer's initial public offering without payment of consideration. The Series A-1 Preferred Stock… Full note on SEC EDGAR

Jul 24, 2026

Behzad Aghazadeh - Director

Open-market purchase

Common Stock, par value $0.0001 per share

2,333,333

$15.00^{footnote F1}

$35.00M

Jul 24, 2026

Behzad Aghazadeh - Director

Open-market purchase

Common Stock, par value $0.0001 per share

50,000

$22.31^{footnote F2}

$1.12M

Jul 28, 2026

Behzad Aghazadeh - Director

Open-market purchase

Common Stock, par value $0.0001 per share

7,905

$18.25^{footnote F2}

$144K

Footnote F1 (price): The shares reported on this line were purchased from underwriters in the Issuer's initial public offering (the "IPO") at the initial public offering price of $15.00 per share. Of such shares, 2,066,666 shares were purchased on behalf of Avoro Life Sciences Fund LLC ("Avoro Life… Full note on SEC EDGAR
Footnote F2 (price): The shares reported on these lines were purchased on behalf of Avoro Life Sciences in open market transactions on the dates provided in Column 2.

Mar 13, 2026

Brett Staahl - 10% Owner

Grant or award

Stock Option (Right to Buy)

4,755

$0.00

Jul 23, 2026

Brett Staahl - 10% Owner

Grant or award

Stock Option (Right to Buy)

19,385

$0.00